Molecular Tumor Immunology Laboratory(분자종양면역학연구실)

Chang-Woo Lee

분자종양학, 종양면역학, 자가면역 Laboratory
1. Tumor biology and Anti-tumor immunity
: Identifications of novel signaling pathways in tumor immunity and immune checkpoint regulation
2. Autoimmunity and autoimmune disease therapy
: Receptor-mediated signaling mechanism in regulating autoimmunity and the development of autoimmune disease therapeutic strategy
3. Hepatic metabolic disorders and hepatocellular carcinoma
: Study of novel molecular mechanism of steatohepatitis and hepatocellular carcinoma, and development of its relevant therapeutic strategy
1. Ssu72 phosphatase is essential for the physiological parameters of adipose tissue maintenance and thermogenesis. Molecular Cell 2020 (in revision) (IF 14.548).
2. Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks. Nature Communications 2019 10:1577: 1-18. (IF 12.353)
3. De novo phosphorylation of H2AX by WSTF regulates transcription-coupled homologous recombination repair. Nucleic Acids Research 2019 9:47 6299-6314. (IF 12.353)
4. Peli1 ively Targets Kinase-Active RIP3 for Ubiquitylation-Dependent Proteasomal Degradation. Molecular Cell 2018, 7(70):920-935 (IF 14.248).
5. The chromatin remodeler RSF1 controls centromeric histone modifications to coordinate chromosome segregation. Nature Communications 2018, (IF 12.353)
6. Hepatocyte homeostasis for chromosome ploidization and liver function is regulated by Ssu72 protein phosphatase. Hepatology 2015, 63(2016): 247-259 (IF 14.079)
7. Pellino1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. Journal of Clinical Investigation 2014, 124(11): 4976-4988 (IF 13.251)
8. The chromatin remodeller RSF1 is essential for PLK1 deposition and function at mitotic kinetochores. Nature Communications 2015, 6(7904):1-14 (IF 12.353)
9. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 pateints. Nature Communications 2014, 5(5317):1-14 (IF 12.353)
10. The condensin component NCAPG2 regulates microtubule-kinetochore attachment through recruitment of Polo-like kinase 1 to kinetochores. Nature Communications 2014, 4588(5):1-13 (IF 12.353)
11. Functional interplay between Aurora B kinase and Ssu72 phosphatase regulates sister chromatid cohesion. Nature Communications 2013, 4(2631): 1-14 (IF 12.353)
12. Roles of 14-3-3η in mitotic progression and its potential use as a therapeutic target for cancers. Oncogene 2013, 32(12): 1560-1569 (IF 8.559)
13. TNKS 1 function at telomere and during mitosis is regulated by Polo-like kinase 1-mediated phosphorylation. Cell Death and Differentiation 2012, 19(2): 321-32 (IF 8.385)
14. The hsSsu72 phosphatase is a cohesion-binding protein that regulates the resolution of sister chromatid arm cohesion. EMBO Journal 2010, 29(20): 3544-3557 (IF 10.748)
15. Functional interaction between BubR1 and securin in an APCCdc20-independent manner. Cancer Research 2009, 69(1): 27-36 (IF 9.248)
16. Mitotic catastrophe is the predominant response to histone acetyltransferase depletion. Cell Death and Differentiation 2009, 16(3): 483-497 (IF 9.284)
17. p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Research 2007, 67(15): 7155-7164 (IF 9.284)
18. STAT4 expression in human T cells is regulated by DNA methylation but not by promoter polymorphism. Journal of Immunology 2005, 175(11): 7143-7150
19. Transcriptional abnormality of hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Research 2004, 64(23): 8666-8673 (IF 9.284)
20. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2004, 4: 483-497 (IF 23.893)
21. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Nature Review Cancers 2004, 4: 91 (IF 37.912).
22. Inhibition of histone deacetylase activity increases the chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003, 22(25): 3853-3858 (IF 8.559).
(Tel) +82-31-299-6121,  (Email)